Arrhythmogenic Cardiomyopathy research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE2
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
This study is testing a new drug called Tideglusib for a heart condition called Arrhythmogenic Cardiomyopathy (ACM). It aims to see if the drug can help improve the condition by targeting specific pathways in the heart. The study is in its early stages.
Canada - recruiting
Mayo AVC Registry and Biobank
This study aims to better understand a heart condition called Arrhythmogenic Ventricular Cardiomyopathy (AVC) that can lead to sudden cardiac arrest. Researchers hope to find new genetic causes and ways to predict the disease, helping to save lives in affected families.
United States · United Kingdom - recruiting
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
This study looks at how a heart condition called ARVC, caused by a gene fault (PKP2), progresses naturally. It also checks for common antibodies that could affect future gene therapy. It's for people aged 14-65 with ARVC and a specific gene change.
United States · France · Germany